Home > Research > Publications & Outputs > Mometasone Furoate significantly reduces radiat...
View graph of relations

Mometasone Furoate significantly reduces radiation dermatitis in patients undergoing breast radiation therapy: a double-blind randomized control trial in 120 patients

Research output: Contribution to journalMeeting abstract

Published
Close
<mark>Journal publication date</mark>10/2013
<mark>Journal</mark>International Journal of Radiation Oncology - Biology - Physics
Issue number2 Supplement
Volume87
Number of pages1
Pages (from-to)S115
Publication StatusPublished
<mark>Original language</mark>English
EventAmerican Society for Radiation Oncology - Georgia World Congress Center, Atlanta, United Kingdom
Duration: 22/09/201325/09/2013

Conference

ConferenceAmerican Society for Radiation Oncology
CountryUnited Kingdom
CityAtlanta
Period22/09/1325/09/13

Abstract

The most common acute side effect of patients receiving radiation therapy to the breast/chest wall is radiation induced dermatitis. Despite this, there is no accepted intervention to prevent or treat it. A previous study by Bostrom et al showed Mometasone Furoate (M) cream was superior to Diprobase (D) in a study of 50 breast cancer patients. We sought to repeat this study in a larger cohort of 120 patients.